Cleavage fragments of the third complement component (C3) enhance stromal derived factor-1 (SDF-1)-mediated platelet production during reactive postbleeding thrombocytosis

Leukemia

Volumn 21, Issue 5, 2007, Pages 973-982

  Wysoczynski, M ^a   Kucia, M ^a   Ratajczak, J ^a   Ratajczak, M Z ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3[DEARGININE]; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CELL ADHESION; CELL MATURATION; CELL MIGRATION; CELL STIMULATION; CELL STRESS; CHEMOTAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID RAFT; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS;

EID: 34247574748     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404629     Document Type: Article

References (40)

1. Long MW, Hoffman R (eds). Hematology: Basic Principles and Practice Churchill Livingstone: New York, 1999, p245.
2. Gewirtz AM. Megakaryopoiesis: State of the art. Thromb Haemost 1995; 74: 204-209.
3. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445-1447.
4. Gurney AL, de Sauvage FJ. Dissection of c-Mpl and thrombopoietin function: Studies of knockout mice and receptor signal transduction. Stem Cells 1996; 14 (Suppl 1): 116-123.
5. Bunting S, Widmer R, Lipari T, Rangell L, Steinmetz H, Carver-Moore K et al. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997; 90: 3423-3429.
6. Sasaki H, Hirabayashi Y, Ishibashi T, Inoue T, Matsuda M, Kai S et al. Effects of erythropoietin, IL-3, IL-6 and LIF on a murine megakaryoblastic cell line: Growth enhancement and expression of receptor mRNAs. Leuk Res 1995; 19: 95-102.
7. Burstein SA, Mei RL, Henthorn J, Friese P, Turner K. Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992; 153: 305-312.
8. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R et al. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993; 81: 901-908.
9. Majka M, Ratajczak J, Villaire G, Kubiczek K, Marquez LA, Janowska-Wieczorek A et al. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. Exp Hematol 2002; 30: 751-760.
10. Gainsford T, Nandurkar H, Metcalf D, Robb L, Begley CG, Alexander WS. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000; 95: 528-534.
11. Wang JF, Liu ZY, Groopman JE. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 1998; 92: 756-764.
12. Hamada T, Mohle R, Hesselgesser J, Hoxie J, Nachman RL, Moore MA et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 1998; 188: 539-548.
13. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 1999; 104: 220-229.
14. Riviere C, Subra F, Cohen-Solal K, Cordette-Lagarde V, Letestu R, Auclair C et al. Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood 1999; 93: 1511-1523.
15. Hodohara K, Fujii N, Yamamoto N, Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 2000; 95: 769-775.
16. Majka M, Janowska-Wieczorek A, Ratajczak J, Kowalska MA, Vilaire G, Pan ZK et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 2000; 96: 4142-4151.
17. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71.
18. Nguyen DH, Taub D. CXCR4 function requires membrane cholesterol: implications for HIV infection. J Immunol 2002; 168: 4121-4126.
19. Gu Y, Filippi MD, Cancelas JA, Siefring JE, Williams EP, Jasti AC et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003; 302: 445-449.
20. Wysoczynski M, Reca R, Ratajczak J, Kucia M, Shirvaikar N, Honczarenko M et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005; 105: 40-48.
21. Quinton TM, Kim S, Jin J, Kunapuli SP. Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost 2005; 3: 1036-1041.
22. Reca R, Mastellos D, Majka M, Marquez L, Ratajczak J, Franchini S et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 2003; 101: 3784-3793.
23. Ratajczak MZ, Reca R, Wysoczynski M, Kucia M, Baran JT, Allendorf DJ et al. Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia 2004; 18: 1482-1490.
24. Ratajczak MZ, Kucia M, Reca R, Majka M, Janowska-Wieczorek A, Ratajczak J. Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow. Leukemia 2004; 18: 29-40.
25. Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev 2001; 15: 159-166.
26. Christenson JT. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg 1999; 15: 394-399.
27. Goldfarb RD, Parrillo JE. Complement. Crit Care Med 2005; 33 482-484.
28. Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/ acylation-stimulating protein. J Biol Chem 2003; 278: 11123-11129.
29. Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood 2000; 96: 4152-4159.
30. Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-arg. J Exp Med 1983; 158: 603-615.
31. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201: 871-879.
32. Biro E, Akkerman JW, Hoek FJ, Gorter G, Pronk LM, Sturk A et al. The phospholipid composition and cholesterol content of platelet-derived microparticles: A comparison with platelet membrane fractions. J Thromb Haemost 2005; 3: 2754-2763.
33. Colli S, Werba JP, Tremoli E. Statins in atherothrombosis. Semin Vasc Med 2004; 4: 407-415.
34. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
35. Aoe K, Hiraki A, Yamazaki K, Nakamura Y, Murakami T, Maeda T et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71: 170-173.
36. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752-760.
37. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles (MV): Important and underappreciated mediators of cell to cell communication. Leukemia 2006; 20: 1487-1495.
38. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006; 20: 847-856.
39. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942.
40. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959-968.